title: [Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
abstract: A Phase I trial of irinotecan hydrochloride (CPT-11) was performed to determine the maximum tolerated dose (MTD), the dose-limiting toxicities, and the incidence and severity of other toxicities in children with advanced neuroblastoma. Three children received 11 courses of CPT-11 administered as a 90-min i.v. infusion, daily for 3 days every 21 days. Doses ranged from 100 mg/m2 to 220 mg/m2. Two peaks in the total number of instances of diarrhea was observed, 25 stools at 3 days and 32 stools at 10 days. Myelosuppression was well controlled and of brief duration. One child achieved a clinical complete response (CR) and 2 had a partial response (PR). The MTD of CPT-11 administration was 180 mg/m2 for 3 days. These results indicate the usefulness of CPT-11 for the treatment of advanced neuroblastoma. Further investigation is necessary to establish its role in combination chemotherapeutic regimens.
authors.affiliation: Dept. of Pediatrics, Aichi Medical University.
authors.forename: T
authors.initials: T
authors.lastname: Hirota
authors.forename: N
authors.initials: N
authors.lastname: Kawai
authors.forename: S
authors.initials: S
authors.lastname: Kitagawa
authors.forename: T
authors.initials: T
authors.lastname: Hori
authors.forename: K
authors.initials: K
authors.lastname: Konno
authors.forename: K
authors.initials: K
authors.lastname: Sawada
authors.forename: H
authors.initials: H
authors.lastname: Agata
authors.forename: T
authors.initials: T
authors.lastname: Fujimoto
authors.forename: M
authors.initials: M
authors.lastname: Tsurusawa
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000188:drug therapy*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D000077146:Irinotecan; D009447:Neuroblastoma / Q000188:drug therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D000077146:Irinotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002166:Camptothecin